A new, value-based Cancer Drugs Fund is set to be launched in England soon, but pharma companies fear it will be a step backwards for access to new cancer medicines.
As consultation on the 'new' Cancer Drugs Fund closes this week, Leela Barham reviews the impact of England's guidance on end-of-life treatments and the implications of these broader changes.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
